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Anxiety disorders, depression and pain are highly prevalent pathologies. Their
pharmacotherapy is associated with unwanted side effects; hence there is a
clinical need to develop more effective drugs with fewer adverse reactions.
Chalcones are one of the major classes of naturally occurring compounds.
Chalcones and their derivatives have a huge importance in medicinal chemistry,
displaying a wide range of pharmacological activities including anti-
inflammatory, antimicrobial, antioxidant, cytotoxic and antitumor actions.
The aim of this work was to evaluate chalcone effects on different targets involved
in these pathologies. We have synthesized a series of simple chalcone derivatives
taking common structural requirements described in literature related to their.e01376
vier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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Furthermore, their potential in vitro effects towards different targets involved in
these pathologies were evaluated. We have obtained twenty chalcones with
moderate to high yields and assessed their ability to bind distinctive receptors,
from rat brain homogenates, by displacement of labelled specific ligands: [3H]
FNZ (binding site of benzodiazepines/GABAA), [
3H] 8-OH-DPAT (serotonin 5-
HT1A) and [
3H] DAMGO (m-opioid). Those compounds that showed the better
in vitro activities were evaluated in mice using different behavioural tasks.
In vivo results showed that 50-methyl-20-hydroxychalcone (9) exerted anxiolytic-
like effects in mice in the plus maze test. While chalcone nuclei (1) revealed
antidepressant-like activities in the tail suspension test. In addition, the novel 50-
methyl-20-hydroxy-30-nitrochalcone (12) exhibited antinociceptive activity in
acute chemical and thermal nociception tests (writhing and hot plate tests). In
conclusion, chalcones are thus promising compounds for the development of
novel drugs with central nervous system (CNS) actions.
Keywords: Biochemistry, Neuroscience, Pharmaceutical chemistry, Pharmaceutical
science1. Introduction
Natural sources are still one of the most important inspirations for the discovery and
design of new chemical entities as potential drugs [1]. Chalcones (1,3-diaryl-2-
propen-1-ones) (Fig. 1) belong to the flavonoid family. Chemically they consist of
two aromatic rings joined by a three-carbon a,b-unsaturated carbonyl system [2].
Natural and synthetic chalcone derivatives have shown promising biological activ-
ity, safety profiles and potential as lead compounds for the discovery of antioxidant,
anti-inflammatory, anticancer, anti-infective agents, among others [3]. It was re-
ported that simple and synthetically produced chalcones represent a new challengeFig. 1. Synthesis of compounds 2e21. Reagents and conditions: i) MeOH, NaOH (50%), 70 C, 3e5 h.
For fluorinated derivatives NaOH (25%) was used.
on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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importance of these compounds [1].
Anxiety disorders, depression and pain represent some of the most common and
proliferating health problems that affect a large percentage of the population world-
wide. Individuals suffering from these pathologies are faced with considerable
disruption of their quality of life, psychological well-being and greater risk for
various somatic conditions [4, 5, 6]. Despite the existence of anxiolytic, antidepres-
sant and pain relief drugs, there is a need to develop more effective pharmacother-
apies with fewer side effects than the existing drugs [7, 8]. The endogenous gamma
aminobutyric acid (GABA), serotonergic and opioid systems are critical for the
regulation of many physiological and behavioural functions. Specially for these
diseases, GABA type A receptors (GABAA) can be allosterically modulated by
different drugs such as benzodiazepines (BDZs) causing anxiolytic effects [9].
Within the seven main classes of 5-HT (serotonin) receptors, 5-HT1A subtype plays
an important role in the regulation of mental disorders such as depression, anxiety
or schizophrenia [10]. On the other hand, of three known ‘classical’ types of opioid
receptors (m, d and k), m-opioid receptor is thought to be primarily responsible for
the mediation of opioid antinociception [11]. Thus, in vivo activities of anxiolytic,
antidepressant and antinociceptive drugs could be related to these biological
targets.
In this work, we have made a survey of bibliographic reports of simple chalcones
with anxiolytic, antidepressant and antinociceptive activities to recognize com-
mon structural determinants (see Table 1). Only few natural and synthetic chal-
cones have been reported in relation to these pathologies, therefore revealing
chalcones as promising scaffold for the development of new derivatives. Most
of the reported compounds have a hydroxyl group substitution in position 20.
Also, methoxy, methyl, dimethylamine, halogens and nitro groups substitutions
are present in both rings of these derivatives. Additionally, the natural compound
isoliquiritigenin (20,40,4-trihydroxychalcone) was described as a ligand for the
benzodiazepine binding site (BDZ-bs) of the GABAA receptor, with a Ki value
of 0.45 mM, being a positive allosteric modulator [12]. Also, we have already re-
ported that the chalcone nucleus itself exhibits moderate affinity for the m-opioid
receptor [13].
Thus, the aim of this work was to synthesize a series of simple chalcones and assess
their potential effect on different biological receptors involved in anxiety disorders,
depression and pain. Afterwards, those compounds of the series that showed the best
affinity for each receptor were tested in different behavioural paradigms related to
these pathologies.on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Reported simple chalcones with anxiolytic-like, antidepressant-like and antinociceptive activities in rodents.
Name R2’ R3’ R4’ R5’ R6’ R2 R3 R4 R5 R6 Ref.
Chalcones with anxiolytic-like effect
Isoliquiritigenin OH H OH H H H H OH H H [14]
Butein OH H OH H H H OH OH H H [14]
Chalcones with antidepressant-like effect
Isoliquiritin OH H OH H H H H O-b-Glc H H [15]
Isoliquiritigenin OH H OH H H H H OH H H [16]
Butein OH H OH H H H OH OH H H [17]
4,20,40,60- tetrahydroxychalcone OH H OH H OH H H OH H H [18]
3,4,20,40,60-pentahydroxychalcone OH H OH H OH H OH OH H H [18]
3-methoxy-4,20,40,60-tetrahydroxychalcone OH H OH H OH H OCH3 OH H H [18]
2-bromo-20,40,60-trihydroxychalcone OH H OH H OH Br H H H H [18]
3-bromo-20,40,60-trihydroxychalcone OH H OH H OH H Br H H H [18]
3-bromo-20,40-dihydroxychalcone OH H OH H H H Br H H H [16]
2-fluoro-20,40,60-trihydroxychalcone OH H OH H OH F H H H H [18]
3-chloro-20,40,60-trihydroxychalcone OH H OH H OH H Cl H H H [18]
4-chloro-20,40,60-trihydroxychalcone OH H OH H OH H H Cl H H [18]
2,4-dichloro-20,40,60-trihydroxychalcone OH H OH H OH Cl H Cl H H [18]
2,6-dichloro-20,40-dihydroxychalcone OH H OH H H Cl H H H Cl [16]
(continued on next page)
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Table 1. (Continued )
Name R2’ R3’ R4’ R5’ R6’ R2 R3 R4 R5 R6 Ref.
Chalcones with peripheral antinociceptive effect
Chalcone H H H H H H H H H H [19]
40-chlorochalcone H H Cl H H H H H H H [19]
40-bromochalcone H H Br H H H H H H H [19]
30,40-dichlorochalcone H Cl Cl H H H H H H H [19]
4,30,40-trichlorochalcone H Cl Cl H H H H Cl H H [19]
30,40-dichloro-4-dimethylaminechalcone H Cl Cl H H H H (-N(CH3)2) H H [19]
40,60-dimethoxy-20-hydroxychalcone OH H OCH3 H OCH3 H H H H H [20]
4,40,60-trimethoxy-20-hydroxychalcone OH H OCH3 H OCH3 H H OCH3 H H [20]
40,60-dimethoxy-4-methyl-20-hydroxychalcone OH H OCH3 H OCH3 H H CH3 H H [20]
6-chloro-40,60-dimethoxy-20-hydroxychalcone OH H OCH3 H OCH3 H H H H Cl [20]
3,4-dichloro-40,60-dimethoxy-20-hydroxychalcone OH H OCH3 H OCH3 H Cl Cl H H [20]
40,60-dimethoxy-20-hydroxy-3-nitrochalcone OH H OCH3 H OCH3 H NO2 H H H [20]
40,60-dimethoxy-20-hydroxy-4-nitrochalcone OH H OCH3 H OCH3 H H NO2 H H [20]
30-bromo-40,60-dimethoxy-20-hydroxychalcone OH Br OCH3 H OCH3 H H H H H [20, 21]
30-bromo-40,60-dimethoxy-20-hydroxy-3-
nitrochalcone
OH Br OCH3 H OCH3 H NO2 H H H [20]
6-chloro-30-bromo-40,60-dimethoxy-20-
hydroxychalcone
OH H OCH3 H OCH3 H H H H Cl [20]
2-hydroxychalcone H H H H H OH H H H H [22]
(continued on next page)
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Table 1. (Continued )
Name R2’ R3’ R4’ R5’ R6’ R2 R3 R4 R5 R6 Ref.
40-methyl-2-hydroxychalcone H H CH3 H H OH H H H H [22]
40-methoxy-2-hydroxychalcone H H OCH3 H H OH H H H H [22]
40-chloro-2-hydroxychalcone H H Cl H H OH H H H H [22]
40-bromo-2-hydroxychalcone H H Br H H OH H H H H [22]
30,40-dichloro-2-hydroxychalcone H Cl Cl H H OH H H H H [22]
2-hydroxy-40-nitrochalcone H H NO2 H H OH H H H H [22]
Chalcones with central antinociceptive effect
20,40,4,5-tetrahydroxychalcone OH H OH H H H H OH OH H [23]
20,40-dimethoxy-60-hydroxychalcone OCH3 H OCH3 H OH H H H H H [24]
3,4-methylenedioxy-40,60-dimethoxy-20-
hydroxychalcone
OH H OCH3 H OCH3 H M M H H [21]
40,60-dihydroxy-30,50-dimethyl-20-methoxychalcone OCH3 CH3 OH CH3 OH H H H H H [25]
R2’, R3’, R4’, R5’, R6’, R2, R3, R4, R5, R6 represent the substituent as indicated in chalcone structure from Fig. 1.
Sugar moieties: glucose (Glc), M: methylenedioxy.
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2.1. Chemistry
2.1.1. General
20-hydroxyacetophenone, 20-hydroxy-40-methoxyacetophenone, 20-hydroxy-50-me-
thoxyacetophenone, 20-hydroxy-60-methoxyacetophenone, 50-chloro-20-hydroxya-
cetophenone, 50-fluoro-20-hydroxyacetophenone, 50-bromo-20-hydroxy
acetophenone, 20-hydroxy-50-methylacetophenone, 20-hydroxy -30,50-dibromoaceto-
phenone, 20-hydroxy- 40,50-dimethylacetophenone, 20-hydroxy-50-methyl-30-
nitroacetophenone, 40-hydroxy-30-methoxyacetophenone, 40-aminoacetophenone,
40-methylacetophenone and 4-dimethylaminobenzaldehyde were obtained from
Sigma-Aldrich Chemical Company. Benzaldehyde was purchased from
Mallinckrodt Pharmaceuticals. Acetophenone, 3-chlorobenzaldehyde and 4-
chlorobenzaldehyde were obtained from Fluka and 3-nitrobenzaldehyde and 4-
nitrobenzaldehyde from Acros Organics. All solvents were obtained commercially
from Sigma-Aldrich and Fluka.
The reaction progress and product were analyzed by TLC on silica gel on polyester
sheets, with 254 nm fluorescent indicator (Sigma, USA) and by HPLC performed us-
ing C18 reversed phase Vydac columns (The Separation Group, Hesperia, CAL,
USA). Purity and structures of the obtained compounds were confirmed by chromato-
graphic (TLC, HPLC) and spectroscopic (NMR, MS) methods. 1H NMR and 13C
RMN spectra were recorded in a Criomagneto Bruker-Oxford BZH 300/89 of 7.05
Tesla apparatus. Electrospray ionization ion trap mass spectra were recorded on a
LCQ-Duo (ESI-IT) spectrometer ThermoFisher. Elemental (C, H, N) analysis was car-
ried out on Carlo Erba 1108 analyzer and Exeter CE 440. Analysis indicated by the
symbols of the elements or functions were within 0.4 % of the theoretical values.
cLog P values of the compounds were calculated using ChemDraw Ultra 12.0.
[3H]-flunitrazepam (FNZ), [3H]-8-hydroxy-2-(dipropylamine)tetralin ([3H]-8-OH-
DPAT) and [3H]-DAMGO ([D-Ala2, N-Me-Phe4, Gly-ol5] enkephalin) were
obtained from Perkin Elmer Life and Analytical Sciences, Boston, MA, USA. Diaz-
epam (DZ) was obtained from Roche Diagnostics. Naltrexone hydrochloride, imip-
ramine hydrochloride (IMP) and serotonin hydrochloride were obtained from
Sigma-Aldrich Chemical Company, USA. Morphine hydrochloride (MOR) was ob-
tained from Gramon Millet (Argentina).2.1.2. General methods for the synthesis of 2-21
The synthesis of the chalcone derivatives was performed following [26] with some
modifications (Fig. 1): To a stirred solution of each acetophenone (1 mmol) and benz-
aldehyde (1 mmol) in MeOH (10 mL), 1 mL of a 50% aqueous solution of NaOH wason.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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was neutralized with HCl 10% and extracted with CH2Cl2. The organic layer was dried
over anhydrous Na2SO4, filtered, concentrated under reduced pressure and recrystal-
lized from MeOH/H2O. In the case of fluorinated derivatives NaOH (25%) was
used. HPLC purity of all the chalcone derivatives were >98%.
2.1.2.1. (2E)-1-(2-hydroxyphenyl)-3-phenyl-2-propen-1-one (2)
Yield 85 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 12.85 (s, 1H),
7.98e7.93(m, 2H), 7.72e7.67 (m, 3H), 7.56e7.45 (m, 4H), 7.07e6.95 (m, 2H).
13C NMR (75 MHz, CDCl3) d 193.76, 163.62, 145.50, 136.43, 134.62, 130.95,
129.66, 129.06, 128.68, 120.03, 120.03, 118.87, 118.67. MS: m/z 225.0
[Mþ1H]þ (C15H12O2).
2.1.2.2. (2E)-1-(2-hydroxy-4-methoxyphenyl)-3-phenyl-2-propen-1-
one (3)
Yield 34 %, orange crystals. 1H NMR (300MHz, CDCl3) d 13.46 (s, 1H), 7.90 (d, J¼
15.58 Hz, 1H), 7.85 (d, J¼ 9 Hz, 1H), 7.67e7.62 (m, 2H), 7.59 (d, J¼ 15.48 Hz, 1H),
7.45e7.44 (m, 3H), 6.52e6.49 (m, 2H), 3.88 (s, 3H). 13C NMR (75 MHz, CDCl3)
d 191.85, 166.72, 166.24, 144.41, 134.79, 131.24, 130.66, 128.99, 128.53, 120.33,
114.09, 107.78, 101.08, 55.61. MS: m/z 255.0 [Mþ1H]þ (C16H14O3).
2.1.2.3. (2E)-1-(2-hydroxy-5-methoxyphenyl)-3-phenyl-2-propen-1-
one (4)
Yield 76 %, orange oil. 1H NMR (300 MHz, CDCl3) d 12.39 (s,1H), 7.95 (d, J ¼
15.45 Hz, 1H), 7.71e7.66 (m, 2H), 7.63 (d, J ¼ 15.48 Hz, 1H), 7.48e7.42(m,
3H), 7.39e7.38(m, 1H), 7.19e7.12 (m, 2H), 3.87 (s, 3H). 13C NMR (75 MHz,
CDCl3) d 193.40, 157.97, 151.75, 145.61, 134.61, 130.96, 129.06, 128.67,
124.14, 120.20, 119.65, 113.56, 56.02. MS: m/z 255.0 [Mþ1H]þ (C16H14O3).
2.1.2.4. (2E)-1-(2-hydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-
one (5)
Yield 70 %, orange oil. 1H NMR (300 MHz, CDCl3) d 13.15 (s, 1H), 7.87e7.85 (m,
2H), 7.65e7.62 (m, 2H), 7.45e7.35 (m, 4H), 6.64 (d, J¼ 8.37 Hz,1H), 6.45 (d, J¼
8.29 Hz,1H), 3.97 (s, 3H). 13C NMR (75 MHz, CDCl3) d 194.49, 164.86, 160.99,
142.94, 135.92, 135.34, 130.30,128.92, 128.47, 127.60, 112.00, 110.97, 101.54,
55.96. MS: m/z 255.0 [Mþ1H]þ (C16H14O3).
2.1.2.5. (2E)-1-(5-chloro-2-hydroxyphenyl)-3-phenyl-2-propen-1-one
(6)
Yield 86 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 12.75 (s, 1H), 7.97 (d, J
¼ 15.46 Hz, 1H), 7.89 (d, J ¼ 1.6Hz, 1H), 7.72e7.70 (m, 2H), 7.60 (d, J ¼ 15.49on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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d 192.77, 161.73, 146.52, 136.15, 134.32, 131.27, 129.11, 128.85, 123,60, 120.62,
120.25, 120.15, 119.50. MS: m/z 260.1/262.3 (rel. 3/1) [Mþ1H]þ (C15H11ClO2).
2.1.2.6. (2E)-1-(5-fluoro-2-hydroxyphenyl)-3-phenyl-2-propen-1-one
(7)
Yield 85 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 12.56 (s, 1H), 7.98 (d, J
¼ 15.43 Hz, 1H), 7.71e7.68 (m, 2H), 7.63e7.59 (m, 1H), 7.57 (d, J ¼ 15.54 Hz,
1H), 7.49e7.46 (m, 3H), 7.30e7.24 (m, 1H), 7.03 (dd, 1H). 13C NMR (75 MHz,
CDCl3) d 192.90, 159.76, 156.45, 146.38, 134.35, 131.22, 129.11, 128.79,
124.09, 119.93, 119.83, 119.56, 114.39. MS: m/z 243.1 [Mþ1H]þ (C15H11FO2).
2.1.2.7. (2E)-1-(5-bromo-2-hydroxyphenyl)-3-phenyl-2-propen-1-one
(8)
Yield 62 %, yellow crystals. 1H NMR (300MHz, CDCl3) d 12.77 (s, 1H), 8.03(d, J¼
2.1Hz 1H), 7.97 (d, J ¼ 15.40 Hz, 1H), 7.72e7.71 (m, 2H), 7.61e7.56 (m, 2H),
7.49e7.48 (m, 3H), 6.96 (d, J ¼ 8.90 Hz, 1H). 13C NMR (75 MHz, CDCl3)
d 192.75, 162.51, 146.60, 138.97, 134.31, 131.85, 131.29, 129.12, 128.87, 121.26,
120.67, 119.42, 110.46. MS: m/z 303.9/305.9 (rel. 1/1) [Mþ1H]þ (C15H11BrO2).
2.1.2.8. (2E)-1-(2-hydroxy-5-methylphenyl)-3-phenyl-2-propen-1-
one (9)
Yield 88 %, orange crystals. 1H NMR (300 MHz, CDCl3) d 12.66 (s, 1H), 7.94 (d, J
¼ 15.49 Hz, 1H), 7.71e7.66 (m, 2H), 7.69 (d, J ¼ 15.51 Hz, 1H), 7.49e7.45 (m,
4H), 7.35 (dd, J ¼ 8.49 Hz, 1.77 Hz, 1H), 6.96 (d, J ¼ 8.46 Hz,1H), 2.38 (s,
3H). 13C NMR (75 MHz, CDCl3) d 193.66, 161.54, 145.26, 137.51, 134.69,
130.87, 129.35, 129.03 (C5), 128.67, 127.93, 120.27, 119.68, 118.39, 20.63. MS:
m/z 239.0 [Mþ1H]þ (C16H14O2).
2.1.2.9. (2E)-1-(3,5-dibromo-2-hydroxyphenyl)-3-phenyl-2-propen-
1-one (10)
Yield 81 %, orange crystals. 1H NMR (300 MHz, CDCl3) d 13.56 (s, 1H), 8.02 (d, J
¼ 15.36 Hz, 1H), 8.01 (d, J¼ 2.10 Hz 1H), 7.91(d, J¼ 2.00 Hz, 1H), 7.72e7.70 (m,
2H), 7.68 (d, J ¼ 15.36 Hz, 1H), 7.50e7.48 (m, 3H). 13C NMR (75 MHz, CDCl3)
d 192.45, 159.24, 147.70, 141.33, 134.08, 131.62, 131.13, 129.18, 129.02, 118.83,
110.34, 109.50. MS: m/z 381.8/383.8/385.8 (rel.1/2/1) [Mþ1H]þ (C15H10Br2O2).2.1.2.10. (2E)-1-(4,5-dimethyl-2-hydroxyphenyl)-3-phenyl-2-propen-
1-one (11)
Yield 45 %, orange crystals. 1H NMR (300 MHz, CDCl3) d 12.71 (s, 1H), 7.92 (d, J
¼ 15.55 Hz, 1H), 7.71e7.69 (m, 4H), 7.47e7.45 (m, 3H), 6.85 (s, 1H), 2.31 (s, 3H),on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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130.72, 129.72, 129.00, 128.61, 127.13, 120.45, 119.16, 117.97, 20.56, 19.04. MS:
m/z 253.0 [Mþ1H]þ (C17H16O2).2.1.2.11. (2E)-1-(5-methyl-3-nitro-2-hydroxyphenyl)-3-phenyl-2-
propen-1-one (12)
Yield 83 %, yellow solid. 1H NMR (300 MHz, CDCl3) d 13.08 (s, 1H), 8.07 (br. s,
1H), 7.96e7.91 (m, 2H), 7.70e7.68 (m, 2H), 7.60 (d, J¼ 15.54 Hz, 1H), 7.49e7.47
(m, 3H), 2.45 (s, 3H). 13C NMR (75 MHz, CDCl3) d 192.19, 154.38, 146.68,
136.92, 136.60, 134.28, 131.35, 130.94, 129.12, 128.88, 128.38, 124.93, 121.37,
20.35. MS: m/z 283.9 [Mþ1H]þ. Anal. Calc. (%) for C16H13NO4: C 67.8, H 4.6,
N 4.9, O 22.6; found: C 67.4, H 4.9, N 4.8, O 22.9.2.1.2.12. (2E)-1-(4-hydroxy-3-methoxyphenyl)-3-phenyl-2-propen-1-
one (13)
Yield 68 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 7.84 (d, J ¼ 15.57 Hz,
1H), 7.69e7.66 (m, 4H), 7.57 (d, J ¼ 15.63 Hz, 1H), 7.45e7.43 (m, 3H), 7.0.2 (d, J
¼ 8.00 Hz, 1H), 4.02 (s, 3H).13C NMR (75 MHz, CDCl3) d 188.55, 150.37, 146.88,
143.96, 135.10, 130.34, 129.27, 128.36, 123.70, 121.70, 113.79, 110.50, 56.16. MS:
m/z 255.0 [Mþ1H]þ (C16H14O3).2.1.2.13. (2E)-1-(4-aminophenyl)-3-phenyl-2-propen-1-one (14)
Yield 70 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 7.96 (d, J ¼ 8.49 Hz,
2H), 7.81 (d, J ¼ 15.66 Hz, 1H), 7.67e7.65 (m, 2H), 7.57(d, J ¼ 15.63 Hz, 1H),
7.43e7.42 (m, 3H), 7.73 (d, 2H), 4.18 (s, 2H). 13C NMR (75 MHz, CDCl3)
d 188.10, 151.08, 143.13, 135.35, 131.09, 131.09, 130.07, 128.87, 128.60,
128.27, 122.07, 113.94, 113.94. MS: m/z 224.1 [Mþ1H]þ (C15H13NO).2.1.2.14. (2E)-1-(4-methylphenyl)-3-phenyl-2-propen-1-one (15)
Yield 35%, white crystals. 1H NMR (300 MHz, CDCl3) d 7.97 (d, J¼ 8.10 Hz, 2H),
7.83 (d, J ¼ 15.66 Hz, 1H), 7.68e7.66 (m, 2H), 7.56 (d, J ¼ 15.72 Hz, 1H),
7.45e7.43 (m, 3H), 7.33 (d, J ¼ 7.95Hz, 2H), 2.44 (s, 3H). 13C NMR (75 MHz,
CDCl3) d 190.04, 144.39, 143.64, 135.67, 135.04, 130.42, 129.25, 128.94,
128.66, 128.40, 122.15, 21.67. MS: m/z 223.1 [Mþ1H]þ (C16H14O).2.1.2.15. (2E)-3-(3-nitrophenyl)-1-phenyl-2-propen-1-one (16)
Yield 35%, white crystals. 1H NMR (300 MHz, dimethyl sulfoxide (DMSO)-d6)
d 8.80 (s ancho, 1H), 8.34e8.26 (m, 1H), 8.23e8.20 (m, 2H), 7.78e7.68on.2019.e01376
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141.92, 137.69, 137.06, 135.57, 133.91, 130.82, 129.34, 129.20, 125.28, 125.15,
123.54. MS: m/z 254.0 [Mþ1H]þ (C15H11NO3).2.1.2.16. (2E)-3-(4-nitrophenyl)-1-phenyl-2-propen-1-one (17)
Yield 35%, whitish crystals. 1H NMR (300 MHz, DMSO-d6) d 8.31e8.13 (m, 7H),
7.84 (d, J ¼ 15.50 Hz, 1H), 7.73e7.71 (m, 1H), 7.63e7.58 (m, 2H); 13C NMR (75
MHz, DMSO-d6) d 189.52, 148.58, 141.60, 137.61, 134.00, 130.36, 129.35, 129.18,
126.55), 124.40, 123.33. MS: m/z 254.0 [Mþ1H]þ (C15H11NO3).2.1.2.17. (2E)-3-(3-chlorophenyl)-1-phenyl-2-propen-1-one (18)
Yield 76 %, reddish oil. 1H NMR (300 MHz, DMSO-d6) d 8.06 (d, J ¼ 15.80 Hz,
1H), 8.00e7.96 (m, 2H), 7.59e7.49 (m, 4H), 7.19e7.00 (m, 4H); 13C NMR (75
MHz, DMSO-d6) d 189.55, 142.75, 137.41, 137.24, 133.81, 133.10, 131.16,
129.29, 129.17, 129.12, 128.47, 128.39, 128.29. MS: m/z 243.0/245.0 (rel. 3/1)
[Mþ1H]þ (C15H11ClO2).2.1.2.18. (2E)-3-(4-chlorophenyl)-1-phenyl-2-propen-1-one (19)
Yield 73%, white crystals. 1H NMR (300 MHz, DMSO-d6) d 8.17 (d, J ¼ 7.3 Hz,
2H), 7.99 (d, J ¼ 15.40 Hz, 1H), 7.95 (d, J ¼ 7.80 Hz, 2H), 7.75 (d, J ¼ 15.80
Hz, 1H), 7.70e7.40 (m, 5H); 13C NMR (75 MHz, DMSO-d6) d 189.58, 143.00,
137.90, 135.59, 134.12, 133.72, 131.08, 129.43, 129.28, 129.03, 123.28. MS: m/z
243.1/245.0 (rel. 3/1) [Mþ1H]þ (C15H11ClO2).2.1.2.19. (2E)-3-[4-(dimethylamino)phenyl]-1-phenyl-2-propen-1-
one (20)
Yield 62 %, yellow crystals. 1H NMR (300 MHz, CDCl3) d 7.78e7.74 (m, 2H),
7.57e7.56 (m, 2H), 7.55e7.54 (m, 3H), 7.48e7.47 (m, 1H), 7.33 (d, J ¼ 15.51
Hz, 1H), 6.73 (d, J ¼ 8.79 Hz, 2H), 3.1 (s, 6H); 13C NMR (75 MHz, CDCl3)
d 190.29, 154.36, 145.76, 139.09,131.98, 130.40, 129.28, 128.32, 125.24, 112.06,
111.02, 40.02. MS: m/z 252.1 [Mþ1H]þ (C17H17NO).2.1.2.20. (2E)-1-(4-aminophenyl)-3-(3-nitrophenyl)-2-propen-1-one
(21)
Yield 62 %, brown crystals. 1H NMR (300 MHz, CDCl3) d 8.53 (s, 1H), 8.26 (d, J¼
8.19 Hz, 1H), 7.98 (d, J¼ 8.58 Hz, 2H), 7.92(d, J¼ 7.92 Hz, 1H), 7.82 (d, J¼ 15.75
Hz, 1H), 7.68 (d, J¼ 15.82 Hz, 1H), 7.60 (d, J¼ 7.90 Hz, 1H), 6.74 (d, J¼ 8.58 Hz,
2H), 4.24 (s, 2H,). 13C NMR (75 MHz, CDCl3) d 186.10, 154.62, 148.91, 139.40,on.2019.e01376
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269.1 [Mþ1H]þ (C15H12N2O3).2.2. Animals, administrations and procedures
2.2.1. Animals
Adult male Swiss mice and adult male Wistar rats (Central Animal House of the
School of Pharmacy and Biochemistry, University of Buenos Aires.), weighing
25e30 g (mice used for the pharmacological tests) and 200e300 g (rats used for
binding assays) were used throughout the study. For behavioural assays mice
were housed in plastic cages, in groups of five, with free access to standard labora-
tory food and water, and kept in a regulated environment (20e23 C) under a 12-h
light/dark cycle (light on at 7:00 AM). Experiments were carried out between 10:00
AM and 2:00 PM and tested by experimenters who were kept unaware of the treat-
ment administered. Behavioural sessions were recorded using a video camera SONY
HDR-AS30/AS30V.
Housing, handling, and experimental procedures complied with the recommenda-
tions and regulations set forth by the National Institutes of Health Guide for Care
and Use of Laboratory Animals (NIH Publication No. 8023, revised 1996) and
the Institutional Committees for the Care and Use of Laboratory Animals of the Fac-
ulty of Pharmacy and Biochemistry, University of Buenos Aires, Argentina (CIC-
UAL, protocol’s approved code numbers: EXP-UBA N: 0031682/2014, Res. N:
3295). Accordingly, to the ARRIVE guidelines, all possible efforts were made to
minimize animal suffering and discomfort and to reduce the number of experimental
subjects. The number of animals used was the minimum number, consistent with ob-
taining significant data. Mice were randomly assigned to any treatment groups and
were used only once.2.2.2. Administrations and procedures
Compounds 1, 9, 12 and DZ were diluted by using the sequential addition of dime-
thylsulfoxide, a solution of 0.25% Tween 80 and saline; up to final concentrations of
5%, 20% and 75%, respectively. MOR and IMP were dissolved in saline solution.
For each assay, a control group receiving only vehicle (VEH) was tested in parallel
with those animals receiving drug treatment. Neither of the tests performed showed
significant differences between VEH control mice vs. mice treated with saline (data
not shown). The volume of intraperitoneally (i.p.) injections was 0.15e0.30 ml/30 g
of body weight. Compounds tested in behavioural assays were evaluated 30 minutes
after i.p. administrations. Doses of the chalcones used for in vivo assays in this study
were chosen based on pilot experiments and previous reports on similar derivatives
(see Table 1).on.2019.e01376
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albumin as standard [27].2.3. Biological activity
2.3.1. In vitro studies
2.3.1.1. Radioligand binding assays
For tissue preparations rats were humanely killed by decapitation and the brains were
removed, washed and rapidly dissected out on ice. Homogenizations were per-
formed by using a PRO Scientific Inc homogenizer at 30,000 rpm for 1 min. Synap-
tosomal membranes were prepared from different brain regions according to
literature as follows: rat cerebral cortex for [3H]-FNZ [28] and 5HT1A [29], rat fore-
brains for [3H]-DAMGO [13]. In all cases membranes were stored at -80 C until
use.
For the [3H]-FNZ (81.8 Ci/mmol) binding assay the compounds were added to 0.2
mg membrane protein thawed and suspended in 1 ml of 25 mM TriseHCl buffer in
the presence of [3H]-FNZ (81.8 Ci/mmol) 0.3 nM. DZ (0.01 nM-600 nM) was used
as positive control. Nonspecific binding was measured in the presence of 10 mM
FNZ. The incubations were carried out at 4 C for 1 h [28].
For the [3H]-8-OH-DPAT binding assay, membranes were suspended in 50 mM
TriseHCl pH 7.4, with 1mM MnCl2 to a final protein concentration of 0.5 mg/
ml. The incubation was performed at 25 C for 1 h in a final volume of 1 ml of mem-
brane suspension in the presence of the compounds and with 0.2 nM of [3H]-8-OH-
DPAT (170.2 Ci/mmol). Serotonin (0.1 nM-300 nM) was used as positive control.
Nonspecific binding was determined in parallel incubations in the presence of sero-
tonin (10 mM) [29].
For the [3H]-DAMGO binding assay, membranes were suspended in 50 mM
TriseHCl pH 7.4 to 0.35 mg/mL final protein concentration. The incubation was
done for 1 h at 25 C in a final volume of 1 mL of membrane suspension in the pres-
ence of the compound and 1 nM of [3H]-DAMGO (56.8 Ci/mmol) [13]. Naltrexone
(0.03 nM-100 nM) was used as positive control. Nonspecific binding was deter-
mined in parallel incubations in the presence of 10 mM naltrexone.
Following incubations, assays were terminated by filtration under vacuum through
Whatman GF/A glass-fiber filters. Then, two or three washing steps with buffer
were performed as follows: 3 ml each wash for the [3H]-FNZ assay (three times),
3 ml each wash for the [3H]-DAMGO assay (two times), 3.5 ml for the [3H]-8-
OH-DPAT assay (three times). Individual filters were incubated overnight with scin-
tillation cocktail (OptiPhase ‘HiSafe’ 3) before measuring radioactivity in a Wallac
Rackbeta 1214 liquid scintillation counter.on.2019.e01376
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tition assays the incubations were done with a range of concentrations (0.1 mM-600
mM) of the compounds.2.3.1.2. Cell viability assay
SH-SY5Y cells (2  104/well in 100 ml) were plated in 96 well microplates and
maintained in Dulbecco’s modified Eagle medium supplemented with 10% fetal
calf serum. The cells were grown in humidified 5% CO2/air on standard plastic cul-
ture dishes. 24e48 h later the medium was removed and the cells were washed and
incubated in complete medium with increasing concentrations (up to 200 mM) of
chalcone (1), 50-methyl-20-hydroxychalcone (9) or 50-methyl-20-hydroxy-30-nitro-
chalcone (12) (dissolved in DMSO). The viability assay was performed 48 h later
by measuring the activity of the lysosome enzyme b-hexosaminidase as described
previously [30].2.3.1.3. PAMPA assay
The in vitro permeability through lipid membrane was determined for 5 commercial
drugs and compounds 1, 9 and 12. The compounds were dissolved in DMSO (10
mM stock solution) and diluted with Prisma HT buffer (5 m L/1 mL at pH ¼ 7.4;
bought from Pion Inc.). Then, the donor 96-well microplate (Millipore filter plate)
was filled with solution of the tested compounds in buffer (200 m L/well). The filter
membrane in acceptor 96-well microplate (Millipore filter plate) was impregnated
with lipid solution (4 m L/well, hexane/dodecane ¼ 1/3; Polar brain lipid extract
20 mg/mL) and the plate was prepared with Brain Sink Buffer (200 m L/well; bought
from Pion Inc.). The acceptor and donor plates were then configured in a »sandwich«
configuration in order to provide contact from lipid filter to the acceptor solution vol-
ume and were left undisturbed for 16 h at 37 C. After incubation, the plates were
separated, well solutions transferred to a UV-plate (Millipore) and concentrations
measured using Biotek Synergy HT microplate reader (l ¼ 230e500 nm in 4 nm
steps). Negative logarithm of the effective permeability (-logPe) was calculated us-
ing the permeability equation under sink conditions published by Avdeef and co-
workers [31] implemented in-house using Python programming language and Py-
thon SciPy library. Assay validation was performed by using the experimental
permeability of the five commercial drugs used as reference standards and binning
as follows: CNSþ, -logPe < 5.6, high permeability; CNSe, -logPe > 6.3, low
permeability; intermediate was labelled as uncertain blood-brain barrier (BBB)
permeability.on.2019.e01376
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2.3.2.1. Elevated plus-maze test
This test is a model to assess anxiety-like responses in rodents based on the general
aversion of rodents to open elevated spaces of the maze.
The apparatus consists of two open arms (25 cm  5 cm) positioned opposite to one
another, separated by a crossing point, and two arms of the same dimension, but en-
closed by walls (15 cm high) forming a cross, with free access to all arms from the
crossing point. The maze was elevated 50 cm from the room floor.
Mice were placed on the crossing point from the maze facing an open arm. The num-
ber of arm entries and the time spent going into open arms were recorded during 5
min under red dim light. The total exploratory activity (number of entries in both
arms) was also determined [32]. Mice were i.p. injected with 10 mg/kg of com-
pounds 1, 9, 14, 15, 16, and 1 mg/kg of DZ (reference compound) or VEH. Com-
pound 9 was further tested at the doses of 3 mg/kg and 30 mg/kg.2.3.2.2. Tail suspension test
The total duration of immobility induced by tail suspension was measured according
to the method of Steru and co-workers [33]. It is a useful mouse behavioral test for
the screening of potential antidepressant drugs [7]. Mice were individually sus-
pended by their tails to a metal hook (distance from floor: 18 cm) with adhesive
tape (distance from tip of tail: 2 cm) for 6 min. Mice, especially at the beginning
of the session, manifest several escape oriented behaviours (which constitute
mobility) interspersed with temporally increasing bouts of immobility. The duration
of immobility was recorded during the last 4 min interval of the test. Mice were
considered immobile only when they hung passively and completely motionless.
Mice were i.p. administered with 10 mg/kg of compounds 1, 5, and 30 mg/kg of
IMP (reference compound) or VEH. Compound 1 was also tested at the doses of
3 mg/kg and 30 mg/kg.2.3.2.3. Antinociceptive assays
2.3.2.3.1. Writhing test
Writhing test is a chemical method used to induce peripheral pain by injection of
acetic acid in mice. Analgesic activity of the test compound is inferred from decrease
in the frequency of writhings. The test was carried out according to Koster et al [34],
with slight modifications. Briefly, mice were i.p. injected with 0.75% acetic acid
aqueous solution (0.2 ml/30 g body weight) and placed in a transparent Plexiglas
chamber (15 cm  15 cm30 cm). Five minutes later the number of writhing re-
sponses (abdominal cramps) was counted for 15 min.on.2019.e01376
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12 (10 mg/kg), MOR (6 mg/kg, reference compound) or VEH. Compound 12 was
subsequently assayed at the doses of 0.3 mg/kg, 3 mg/kg and 30 mg/kg.
Antinociceptive activity after chalcone treatment was expressed as the percentage of
inhibition in the number of abdominal writhes normalized to control group.2.3.2.3.2. Hot plate test
The hot plate test was performed to evaluate sensitivity to acute pain to a thermal
stimulus, most commonly used for determining the antinociceptive efficacy of cen-
trally acting test compounds in rodents [35]. Each mouse was placed into a trans-
parent Plexiglass beaker (18 cm height and 10 cm diameter) to avoid the animals
escaping from the plate which temperature was set at 52.5 C  0.1 C. The latency
time (in s) to the first response: hind paw licking/fanning or jumping, was recorded
with a 45 s cut-off time (to prevent tissue damage). Compounds 6 and 12 at the dose
of 30 mg/kg, MOR (reference compound) 6 mg/kg or VEH were i.p. administered.
Further, the dose of 10 mg/kg of compound 12 was also evaluated in this test.2.3.2.4. Locomotor activity
The spontaneous locomotor activity was automatically measured as previously
described [36] and was expressed as total light beam counts per 5 min. The test
was performed 30 min after the i.p. injection of compounds 1, 9 and 12 (10 mg/
kg and 30 mg/kg) or VEH.2.3.2.5. Rotarod
The Rotarod test is used to assess a possible motor deficit provoked by test com-
pounds. It measures the ability of the mouse to maintain balance on a rotating rod
[37].
The equipment consists of a cylindrical shaft 3 cm diameter and 50 cm long, hori-
zontally placed on a support and connected to a motor via a pulley. The axis is sepa-
rated by discs into five compartments where mice are placed.
Mice were i.p. administered with 30 mg/kg of compound 12 or VEH. Each mouse
was placed on the rotating rod and the latency time to fall off is measured (cut-off
time: 120 s). Previously, mice were subjected to 3 successive trainings, in order to
exclude difference in motivation and motor learning, and only those animals that
kept the balance for 2 min in all sessions were used in the trial.on.2019.e01376
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Binding assays data was analyzed by nonlinear regression fit to one site of specific
bound vs radioligand concentration. Ki values were calculated using the Cheng-
Prusoff/Chou equation (equation 1): Ki ¼ IC50/[1þ(L/Kd)], where Ki refers to the
unlabeled ligand inhibition constant, IC50 is the unlabeled ligand concentration
required to reach 50%-maximal binding, Kd refers to radioactive ligand equilibrium
dissociation constant and L refers to the radioactive ligand concentration. Kd values
for [3H] FNZ, [3H] 8-OH-DPAT and [3H] DAMGO were obtained from literature
and were 2.0 nM, 2.4 nM and 0.5 nM, respectively [38, 39, 40].
The effect of test compounds was evaluated by unpaired t test or one-way analysis of
variance (ANOVA). Post-hoc comparisons between treated and VEH groups were
made using Dunnett multiple comparison test.
A P value <0.05 was considered statistically significant. All data were expressed as
mean  S.E.M. and analyzed with GraphPad Prism 5.00 software.3. Results and discussion
3.1. Chemistry
In Table 2 we present the structures of chalcones that were prepared by Claisen-
Schimdt condensation of the corresponding acetophenone and aromatic aldehydes
with moderate to high yields (34e88%) (Fig. 1). The novel chalcone 12 was char-
acterized by 1H NMR, 13C NMR, mass spectra and elemental analysis.3.2. In vitro binding screening
The capacity of the compounds to inhibit the binding of [3H]-FNZ, [3H]-8-OH-
DPAT and [3H]-DAMGO to rat BDZ-bs of the GABAA receptor, 5-HT1A and m-
opioid receptors, respectively, is shown in Table 3. Those derivatives that showed
more than 60% inhibition of radioligands binding to their respective receptors at
the concentration of 300 mM, were selected to determine their inhibitory constant
(Ki). In all cases, data obtained were best fitted to one site binding hyperbola.
All the synthetic derivatives were able to displace at least one of the radioligands
tested. Some of the synthesized compounds showed affinities in the low micromolar
range towards the BDZ-bs of the GABAA receptor and moderate to no affinity for m-
opioid and 5-HT1A receptors.
In the [3H]-FNZ binding assay the results showed that compound 16 exhibited the
highest affinity with a Ki value of 0.2  0.05 mM, followed by the chalcone nucleus
(1) (Ki: 2.8  1.0 mM). Compounds 9, 14 and 15 presented similar Ki values, near 6on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 2. Molecular structures of the chalcones.
Compound R2’ R3’ R4’ R5’ R6’ R2 R3 R4 R5 R6 cLog P
1 Chalcone H H H H H H H H H H 3.59
2 20-hydroxychalcone OH H H H H H H H H H 3.20
3 40-methoxy-20-hydroxychalcone OH H OCH3 H H H H H H H 3.07
4 50-methoxy-20-hydroxychalcone OH H H OCH3 H H H H H H 3.07
5 60-methoxy-20-hydroxychalcone OH H H H OCH3 H H H H H 3.07
6 50-chloro-20-hydroxychalcone OH H H Cl H H H H H H 3.75
7 50-fluoro-20-hydroxychalcone OH H H F H H H H H H 3.35
8 50-bromo-20-hydroxychalcone OH H H Br H H H H H H 4.02
9 50-methyl-20-hydroxychalcone OH H H CH3 H H H H H H 3.68
10 30,50-dibromo-20-hydroxychalcone OH Br H Br H H H H H H 4.85
11 40,50-dimethyl-20-hydroxychalcone OH H CH3 CH3 H H H H H H 4.17
12 50-methyl-20-hydroxy-30-nitrochalcone OH NO2 H CH3 H H H H H H 3.34
13 30-methoxy-40-hydroxychalcone H OCH3 OH H H H H H H H 3.07
14 40-aminochalcone H H NH2 H H H H H H H 2.78
15 40-methylchalcone H H CH3 H H H H H H H 4.07
16 3-nitrochalcone H H H H H H NO2 H H H 3.31
17 4-nitrochalcone H H H H H H H NO2 H H 3.31
18 3-chlorochalcone H H H H H H Cl H H H 4.14
19 4-chlorochalcone H H H H H H H Cl H H 4.14
20 4-dimethylaminochalcone H H H H H H H N(CH3)2 H H 3.87
21 40-amino-3-nitrochalcone H H NH2 H H H NO2 H H H 2.50
R2’, R3’, R4’, R5’, R6’, R2, R3, R4, R5, R6 represent the substituent as indicated in chalcone structure from Fig. 1.
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Article Nowe01376mM. The overall rank-order of potencies for inhibition (for the active compounds)
was the following: compound 16 > 1 > 9 z 14 z 15 > 3 > 2 > 4.
On the other hand, all the tested compounds exhibited low to medium inhibitory ac-
tivities on the [3H]-8-OH-DPAT binding to 5HT1A receptors present in rat cortex tis-
sues. The results showed that chalcones 1 and 5 presented the lowest Ki values of
this series, with values of 20.8  1.5 mM and 13.3  0.3 mM, respectively.
In the [3H]-DAMGO binding assay the results showed that most of the compounds
displayed low to medium activity, though compounds 6 and 12 showed the highest
activity in this binding assay, with Ki values of 19.4  3.5 mM 13.5  6.9 mM,
respectively (Table 3).
This is the first report describing the potential involvement of the 5-HT1A and m-
opioid receptors on the CNS biological activities of chalcone derivatives.3.3. Pharmacological studies
Those compounds of the series with the highest affinity for each receptor were
selected for further in vivo studies. Then, a cut off value of Ki for each receptor
was chosen to reduce the number of animals for the in vivo assays.3.3.1. Elevated plus-maze test
This test is based on the natural aversion of mice to open and elevated areas, as well
as on their natural spontaneous exploratory behaviour in novel environments. This
assay allows the identification of the anxiolytic-like effects of benzodiazepine-like
drugs after their administration in rodents [32]. Chalcones with Ki values less
than 6 mM in the BDZ-bs radioligand assay; 1, 9, 14, 15 and 16; were chosen to
be tested in this assay. First, mice were tested 30 min after their i.p. injection with
10 mg/kg of the each chalcone (Fig. 2).
ANOVA indicated a significant effect on the number of total arm entries [F(5,80) ¼
3.618, P ¼ 0.0050], the percentage of open arm entries [F(5,80) ¼ 5.074, P ¼
0.0005] and in the time spent in those entries [F(5,80) ¼ 3.113, P ¼ 0.0131]. Com-
parisons between the VEH control group and experimental groups (Dunnett’s test)
indicated that compound 9 significantly increased both the percentage of open
arm entries and the time spent in open arms (P < 0.001 and P < 0.01, respectively),
so this compound presented anxiolytic-like activity at this dose. Meanwhile, com-
pound 16 significantly increased the number of total arm entries (P < 0.001).
Alternatively, mice i.p. injected with DZ (1 mg/kg), a classical benzodiazepine
ligand used as a reference compound, showed a significant increase in the three pa-
rameters (P < 0.001, Fig. 2, inset).on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 3. Activities of the chalcone derivatives on the BDZ-bs of the GABAA, 5-HT1A and m-opioid
receptors.
Compound BDZ-bs 5-HT1A m-opioid
Binding inhibitiona
(%) [300 mM]
Kib (mM) Binding
Inhibitiona
(%) [300 mM]
Kib (mM) Binding inhibitiona
(%) [300 mM]
Kib (mM)
1 þþþþ 2.8  1.0 þþþ 20.8  1.5 þþþ 28.2  9.9[13]
2 þþþ 17.1  1.3 þþþ 71.4  1.4 þ nd
3 þþþ 9.0  1.2 þ nd þ nd
4 þþþ 45.7  1.3 þþþ 303  1.2 þþþ 54.6  2.9
5 - nd þþþþ 13.3  0.3 þþþ 26.7  1.6
6 þþ nd þþ nd þþþ 19.4  3.5
7 þþ nd þþþ 129  2.7 þþþ 29.5  6.6
8 þþ nd þþ nd þ nd
9 þþþ 6.1  1.5 þþ nd þþþ 46.3  1.6
10 - nd þþþ 1221  469 þþþ 32.5  9.3
11 þ nd þþþ 164  1.47 þþþ 29.1  8.5
12 þ nd - nd þþþþ 10.8  3.6
13 þþ nd þþ 287.8  1.9 þþ 101  21
14 þþþ 6.1  0.2 þþ nd þþþ 59.4  1.5
15 þþþ 6.3  0.8 þþ nd þ nd
16 þþþþ 0.2  0.05 þþ nd - nd
17 - nd - nd þ nd
18 þþ nd þ nd þ nd
19 þ nd - nd þ nd
20 - nd þþþ 59.6  1.5 þþþ 23.8  3.1
21 þþ nd þþþ 473  7.3 þþ 107  17.6
nd: not determined: <60% inhibition at 300 mM.
aCapacity of the compounds to inhibit the binding of [3H]-FNZ to the BDZ-bs of the GABAA receptor, [
3H]-DAMGO to the m-opioid
receptor and [3H]-8-OH-DPAT to the 5HT1A receptor (at 300 mM) indicated as: inhibition >90% (þþþþ); inhibition 60e90% (þþþ);
inhibition 40e60% (þþ); inhibition 20e40% (þ) and inhibition <20% (-).
b Ki  standard error of the mean values (SEM) are means of 2 independent determinations. Diazepam, serotonin and naltrexone, refer-
ence compounds for the BDZ-bs, 5HT1A and m-opioid receptors, gave Ki values of 3.5  1.2 nM, 2.2  0.01 nM and 0.2  0.01 nM,
respectively.
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this dose, as neither of the measured parameters were statistically different compared
to those of the control group.
The effect of 50-methyl-20-hydroxychalcone (9) in this test was further evaluated at 3,
10 and 30 mg/kg (Fig. 3A). ANOVA indicated a significant effect on the number of
total arm entries [F(3,48) ¼ 2.887, P ¼ 0.0459], the percentage of open arm entries
[F(3,48) ¼ 6.439, P ¼ 0.0010] and in the time spent in those entries [F(3,48) ¼on.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 2. Effect of the i.p. administration of chalcone (1), 50-methyl-20-hydroxychalcone (9), 40-aminochal-
cone (14), 40-methylchalcone (15), 3-nitrochalcone (16) (10 mg/kg) and DZ (1 mg/kg, inset) in mice in
the plus maze test. Results are expressed as mean  S.E.M. of total arm entries, percentage of open arm
entries and percentage of time spent in open arms; registered in 5 min sessions. The symbols denote sig-
nificance levels: **P < 0.01, ***P < 0.001, significantly different from vehicle (VEH); Dunnett’s mul-
tiple comparison test after one-way ANOVA (n ¼ 6e32 mice per group).
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had significantly increased the percentage of open arm entries and the time spent in
open arms (P < 0.01, Dunnett’s test) and the total arm entries (P < 0.05, Dunnett’s
procedure) (Fig. 2A), compared to control group, respectively.
Considering that the parameters measured in the elevated plus-maze test depend on
locomotion [41], the effect of the acute administration chalcone 9 in the spontaneous
locomotor activity of mice was evaluated in a separate method (Fig. 3B). The results
evidenced that animals injected with chalcone 9 at 10 and 30 mg/kg did not show
significant differences compared with the control group in the locomotor activity
test ([F(2,34) ¼ 1.618, P ¼ 0.2140], Fig. 3B). Therefore, the changes in the param-
eters measured in the elevated plus-maze test should not be attributed to changes in
mice locomotion, but they should be considered an anxiolytic-like effect of com-
pound 9 at 10 mg/kg.
Even though isoliquiritigenin and butein (Table 1), natural chalcones, showed
anxiolytic-like effect in the plus-maze test [42], 50-methyl-20-hydroxychalcone (9)
is the first synthetic chalcone described as anxiolytic with affinity for the BDZ-bs
of the GABAA receptor.3.3.2. Tail suspension test
The tail suspension test is one of the most widely used model for assessing
antidepressant-like activity in mice. This test is based on the fact that animalson.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. Effect of the i.p. injection of 50-methyl-20-hydroxychalcone (9) in A) the plus-maze (3, 10 and 30
mg/kg) and B) locomotor activity tests (10 and 30 mg/kg) in mice. Results are expressed as mean 
S.E.M. of A) total arm entries, percentage of open arm entries and percentage of time spent in open
arms and B) spontaneous locomotor activity counts; registered in 5 min sessions. The symbols denote
significance levels: *P < 0.05, **P < 0.01, significantly different from vehicle (VEH); Dunnett’s mul-
tiple comparison test after one-way ANOVA (n ¼ 7e21 mice per group).
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develop an immobile posture. Several antidepressant medications reverse the immo-
bility time and promote the occurrence of escape-related behaviour [7]. Also, there is
accumulating evidence for a critical involvement of serotonergic receptors, particu-
larly 5-HT1A, in the pathophysiology and treatment of depression [10, 43, 44, 45].
Several 5-HT1A agonists decrease the duration of immobility in the in the tail sus-
pension test [46]. Considering the role of the 5-HT1A receptor in the
antidepressant-like activity in rodents and humans [47], the potential
antidepressant-like effect of chalcones with the higher affinities for the 5-HT1Aon.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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tively), were evaluated in mice in the tail suspension test, 30 min after their i.p. in-
jection at the dose of 10 mg/kg (Fig. 4A). ANOVA analysis evidenced statically
differences for the immobility time within experimental groups [F(3,45) ¼ 27.21,
P < 0.0001, Fig. 4A]. The comparison between the VEH control group and exper-
imental groups by the Dunnett’s test indicated that chalcone nuclei (1) at 10 mg/kg
(P< 0.001) and IMP (a reference compound, a tricyclic antidepressant mainly acting
as a norepinephrine uptake blocker) at 30 mg/kg (P < 0.001) significantly reduced
the immobility time of mice. In contrast, compound 5 (10 mg/kg) was not active in
this test (Fig. 4A).
The effect of compound 1 at different i.p. doses (3, 10 and 30 mg/kg) is shown in
Fig. 4B. The parameter measured in this test yielded statistically significant differ-
ences in ANOVA analysis [F(3,38) ¼ 6.469, P< 0.0013]. The comparison between
the VEH control group and experimental groups by the Dunnett’s test indicated that
compound 1 at 10 mg/kg and 30 mg/kg (P < 0.001, P < 0.05, respectively) signif-
icantly reduced the immobility time of mice compared to control group. To avoid
false positive results, the spontaneous locomotor activity test was performed at these
doses as a control (Fig. 4C). Compound 1 at 30 mg/kg evidenced a significant in-
crease of the locomotor activity of mice [F(2,22) ¼ 9.131, P ¼ 0.0013]. In this
case, other factors, such as psychostimulant effects, could have affected mice perfor-
mance in the tail suspension test at 30 mg/kg. Therefore, compound 1 only revealed
antidepressant-like activity at 10 mg/kg.
Even though some authors have used the chalcone scaffold to synthesize novel de-
rivatives with a similar antidepressant-like activity, as the one of fluoxetine (selective
serotonin reuptake inhibitor (SSRI) class) in the tail suspension and forced swim-
ming tests (Table 1), the effect of this nucleus per se has not been reported in any
of these studies [16, 18].
The study of the mechanism of action of the reported 3-bromo-20,40-dihydroxychal-
cone and 2,6-dichloro -20,40-dihydroxychalcone (Table 1) showed that they signifi-
cantly increased head-twitches in mice and enhanced the mouse lethality in the 5-HT
induced head-twitch and yohimbine-induced mortality test. These results indicate
that the serotonergic, but not the noradrenergic system, is involved in the
antidepressant-like effect of these compounds [16].
On the other hand, some reports also revealed that several flavonoids may exert their
antidepressant effect by increasing the bioamine content, thereby restraining the re-
uptake of bioamines by synaptosomes or by inhibiting monoamine oxidases (MAO)
activities [48]. For the chalcone nucleous itsef it was already reported an IC50 value
of 1.41  0.070 mM for the hMAO B and no effect for the hMAO A enzymes [49].
So, future experiments should be performed to determine if the mechanism of actionon.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 4. Effect of acute administration of chalcone (1), 60-methoxy-20-hydroxychalcone (5) and IMP
(reference drug) in the tail suspension test in mice. A) Effect of i.p. injection of chalcone (1), 60-me-
thoxy-20-hydroxychalcone (5) (10 mg/kg) and IMP (30 mg/kg) (n ¼ 8e21 mice per group). B) Effect
of chalcone 1 (3, 10 and 30 mg/kg) (n ¼ 8e11 mice per group). C) Effect of chalcone 1 (10 and 30
mg/kg) in the locomotor activity tests in mice (n ¼ 6e13 mice per group). Results are expressed as
mean  S.E.M. of the immobility time (in s) and spontaneous locomotor activity counts; registered in
5 min sessions. Statistical analysis was performed by one-way ANOVA followed by Dunnett’s test.
***P < 0.001, *P < 0.05, **P < 0.01, significantly different from vehicle (VEH).
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HT1A receptors, or whether other mechanisms are needed to develop this effect.3.3.3. Writhing and hot plate tests
Pain remains a significant clinical problem and m-opioid receptor agonists, such as
hydrocodone and morphine, are still the most widely used treatments for moderate
to severe pain. However, the use of opioids to treat pain is limited by unwanted ef-
fects, such as constipation, respiratory depression, tolerance, and dependence. These
side effects also diminish patient’s quality of life, decrease compliance, and are
particularly problematic in long-term chronic users. These limitations of chronic
opioid therapy have spurred drug discovery efforts to develop new analgesic drugs
with an improved therapeutic profile.
The antinociceptive activity of the synthesized chalcones with Ki values under 20
mM towards m-opioid receptors, chalcones 6 and 12, was evaluated against chemical
and thermal noxious stimuli. First, the acetic acid-induced writhing was performed,
as it is a classical model for the assessment of analgesic or anti-inflammatory prop-
erties of new agents. This is one of the most sensitive methods, which is able to
detect antinociception of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics
and other centrally acting drugs [24]. The effect of compounds 6 and 12 at the dose
of 10 mg/kg in this assay is shown in Fig. 5A. ANOVA of the results obtained
yielded statistically significant differences in the number of abdominal cramps
[F(2,26) ¼ 17.55, P < 0.0001]. The comparison between the VEH control group
and experimental groups by the Dunnett’s test indicated that both treated groups
significantly reduced the number of writhes (P < 0.001).
On the other hand, in the hot plate test, a short thermal stimulus is employed. The
behavioural responses measured are considered to be supraspinally integrated re-
sponses, so it is suitable for the evaluation of centrally but not of peripherally acting
antinociceptive drugs. Compounds exhibiting good antinociceptive effect in this
method may be considered as potent analgesics. The effect of compounds 6 and
12 at the dose of 30 mg/kg in this assay is shown in Fig. 5B. Only chalcone 12 at
30 mg/kg caused significant increases in the reaction time of mice against thermal
noxious stimulus [F(2,25)¼ 7.802, P¼ 0.0026], indicating that only this compound
may act by a central mechanism of action. Mice i.p. injected with morphine (MOR)
(6 mg/kg), a classical m opioid receptor and the reference compound, showed no
abdominal cramps (data not shown) and displayed a higher latency time in the hot
plate assay (latency time ¼ 42.6 s  4.2 s).
Anti-inflammatory activities of chalcones remain first in the list of published biolog-
ical active analogs [50], thus its effects in the writhing test is not unexpected. A num-
ber of chalcones and their derivatives have been described as inhibitors of theon.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 5. Antinociceptive effects of 50-chloro-20-hydroxychalcone (6) and 50-methyl-20-hydroxy-30-nitro-
chalcone (12) in mice. A) Effect of the i.p. injection of chalcone 6 and 12 (10 mg/kg) on the acetic
acid induced writhing (n ¼ 6e14 mice per group). B) Effect of the i.p. injection of chalcone 6 and
12 (30 mg/kg) on the hot plate tests (n ¼ 6e12 mice per group). Effect of acute administration of 50-
methyl-20-hydroxy-30-nitrochalcone (12) in C) the acetic acid induced writhing (0.3, 3, 10 and 30 mg/
kg) (n ¼ 6e16 mice per group); D) the hot plate (10 and 30 mg/kg) (n ¼ 8e12 mice per group) and
E) locomotor activity tests (10 and 30 mg/kg) in mice (n ¼ 7e8 mice per group). Results are expressed
as mean  S.E.M. of the number of writhes, the reaction time of mice in the hot plate test and sponta-
neous locomotor activity counts in comparison to control animals (injected with vehicle, VEH). Statis-
tical analysis was performed by one-way ANOVA followed by Dunnett’s test. *P < 0.05, **P < 0.01,
***P < 0.001, compared with the control group.
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idence of chalcones as peripheral analgesic drugs (see Table 1), little is known about
their centrally antinociceptive action and the involvement of the opioid system. Only
few chalcone derivatives were reported as central analgesic acting drugs in chemical
and thermal nociception models in mice (see Table 1 and [23, 24, 51]). Their mech-
anism of action is not well established as the pretreatment with a non-selective
opioid receptor antagonist, naloxone, only reversed the antinociceptive effect of
the rigid 3,4-dihydroxychalcone [51] and the natural dimeric chalcones extracted
fromMyracrodruon urundeuva [23]. In contrast, our study is focused on simple syn-
thetic chalcones as ligands for m-opioid receptors that evidenced central antinocicep-
tive activity.
The antinociceptive effect of compound 12 was further evaluated at 0.3, 3, 10 and 30
mg/kg in the acetic acid-induced writhing (Fig. 5C) and at 10 and 30 mg/kg in the
hot plate test (Fig. 5D). ANOVA evidenced statistically significant differences in the
number of abdominal cramps [F(4,44) ¼ 21.48, P < 0.0001, Fig. 5C] and in theon.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 5D]. The results revealed that the doses of 3, 10 and 30 mg/kg significantly
reduced the number of writhes with 59.7%, 62.6%, 96.1% inhibition of constrictions
compared to VEH control group (P < 0.0001, Dunnett’s test).
The comparison of the latency time in the hot plate test between the VEH control
group and experimental groups by the Dunnett’s test indicated that the dose of 30
mg/kg significantly increased the latency time of mice in this assay (P < 0.001).
Lastly, in order to discard any motor abnormalities that could interfere with the pa-
rameters measured in the writhing and hot plate tests, the spontaneous locomotor ac-
tivity (Fig. 5E) and the balance on the Rotarod assay were measured for chalcone 12.
None of the mice treated with chalcone 12 showed any failure in their locomotion
(Fig. 5E) or to maintain balance on the Rotarod assay (data not shown), evidencing
that this chalcone did not produce neurotoxicity or motor impairment, at the doses
tested. Therefore, the experimental results presented in this work correspond to
genuine antinociceptive effect, as they were not affected by motor abnormalities.
On the other hand, it is important to stress here that none of the chalcone treated an-
imals tested in this work died during the assays.
According to these results, it can be concluded that the antinociceptive activity of
chalcone 12 may occur by central and peripheral mechanisms. Opioids are known
to show analgesic activities in both hot plate and writhing tests by acting on central
and peripheral nociceptive pathways, respectively [52]. Therefore, chalcones scaf-
fold should be also considered for the development of centrally acting antinocicep-
tive drugs.3.3.4. Cell viability assay on the SH-SY5Y cell line
The absence of adverse effects on a cell line of chalcones 1, 9 and 12 was assessed
using a cell viability assay on SH-SY5Y human neuroblastoma cell line (Fig. 6).
After treatment for 48 h, chalcone 1 did not affect the cell viability up to 75 mM,
compound 9 did not modify the cell viability up to 20 mM meanwhile derivative
12 decreased the cell viability at 20 mM or higher. The active compounds 1, 9
and 12 exhibited 95.9%, 88.5% and 74.8% cell viability at 20 mM, respectively, sug-
gesting that these compounds did not significantly reduce cell viability.3.3.5. Bloodebrain barrier permeability assay
As we are interested in developing compounds with activity towards cerebral recep-
tors, it is crucial that they can reach its targets. Fundamental physiochemical features
of CNS drugs are related to their ability to penetrate the BBB and exhibit CNSon.2019.e01376
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 6. Cell viability of cultured SH-SY5Y cells. Cells were treated with different concentrations of com-
pounds 1, 9 and 12 up to 200 mM for 48 h. Cell viability was quantified by measuring the activity of the
endogenous enzyme hexosaminidase. Results are expressed as mean  S.E.M. of Cell viability (% of
Control) performed in triplicate. The control (Ctrl) group was considered as 100% cell viability. ***P
< 0.001 versus vehicle (VEH, DMSO).
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diffusion. Polar molecules are generally poor CNS agents unless they undergo active
transport across the CNS [53]. As summarized in Table 2, cLog P values for com-
pounds 1e21 were above 2; therefore, it can be estimated that they are capable to
cross the BBB and reach its target. Furthermore, BBB permeability of the com-
pounds 1, 9 and 12 was assessed using the parallel artificial membrane permeability
assay (PAMPA-BBB) [54]. Five commercial drugs were used as references to vali-
date the experimental system and establish the permeability range (-logPe of
7.2e4.6). Traditional pampa binning was used as follows; maxPe > 2*10
6 cm/sTable 4. In vitro blood-brain barrier permeability (PAMPA-BBB assay) pre-
diction for commercial drugs and the selected chalcones 1, 9 and 12.
Compounds BBB penetration estimation
-logPe (cm/s)
Mean ± SEM
Predictionc
chalcone (1)a 4.58  0.01 CNSþ
50-methyl-20-hydroxychalcone (9)a 4.60  0.04 CNSþ
50-methyl-20-hydroxy-30-nitrochalcone (12)a 4.47  0.04 CNSþ
sulfasalazinb 7.13  0.04 CNS
haloperidolb 4.67  0.01 CNSþ
propranololb 4.65  0.01 CNSþ
lidokainb 5.14  0.03 CNSþ
risperidonb 4.81  0.005 CNSþ
a Data are means of four replicates (n ¼ 4).
b Data are means of three replicates (n ¼ 3).
c CNSþ, -logPe < 5.6, high permeability; CNSe, -logPe > 6.3, low permeability; intermediate was
labelled as uncertain BBB permeability.
on.2019.e01376
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6 cm/s designated as low perme-
ability and intermediate as uncertain. According to the results summarized in Table
4, all off the tested compounds should be able to cross BBB and reach CNS.4. Conclusions
In conclusion, a series of 20 chalcone derivatives were synthesized by condensa-
tion of the corresponding acetophenone and aromatic aldehydes with moderate
to high yields. Some of the synthesized compounds showed affinities in the low
micromolar range towards the BDZ-bs of the GABAA receptor and moderate to
no affinity for m-opioid and 5-HT1A receptors. The most active compounds for
each receptor were selected for further in vivo studies. Consequently, chalcones
1, 9, 14, 15 and 16 with good affinity for the BDZ-bs of the GABAA receptor, chal-
cones 1 and 5 with affinity for the 5-HT1A receptor and compounds 6 and 12 for the
m-opioid receptor were chosen to be tested as anxiolytics, antidepressants and anti-
nociceptive drugs in widely used pharmacological tests in mice. The results
showed that chalcone 9 (50-methyl-20-hydroxychalcone) exerted anxiolytic-like ef-
fects in the plus maze assay; chalcone 1 (chalcone nuclei) presented antidepressant-
like activity in mice in the tail suspension test; compound 6 (50-chloro-20-hydrox-
ychalcone) exhibited antinociceptive action in an acute chemical induce nocicep-
tion assay, meanwhile the novel 50-methyl-20-hydroxy-30-nitrochalcone (12)
revealed peripheral and central antinociceptive activities either in acute chemical
and thermal nociception tests. Furthermore, all the pharmacological effects
observed were not influenced by motor abnormalities. Additionally, compounds
1, 9 and 12 did not reduce cell viability of SH-SY5Y human neuroblastoma cell
line and displayed the potential to cross the BBB as demonstrated by PAMPA-
BBB assay.
According to the results summarized simple chalcone derivatives are promising
compounds for the development of novel CNS drugs and comprise a promising scaf-
fold in medicinal chemistry for the development of drugs for the treatment of anx-
iety, depression and pain.Declarations
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